Protara Therapeutics (TARA) Long-Term Investments (2021 - 2026)

Protara Therapeutics (TARA) has reported Long-Term Investments for 5 consecutive years, with $41.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Long-Term Investments rose 25.6% year-over-year to $41.6 million; the TTM figure through Mar 2026 stood at $41.6 million (up 25.6% YoY), while the FY2025 annual figure was $42.3 million, changed N/A from the prior year.
• Long-Term Investments fell to $41.6 million in Q1 2026 per TARA's latest filing, from $42.3 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $42.3 million in Q4 2025 and bottomed at $957000.0 in Q3 2025.
• Historically, Long-Term Investments has averaged $21.8 million across 4 years, with a median of $20.6 million in 2022.
• Annual changes were most pronounced in 2023 — Long-Term Investments plunged 90.63% — and 2026, when it climbed 25.6%.
• Protara Therapeutics' Long-Term Investments stood at $17.9 million in 2022, then plunged by 83.83% to $2.9 million in 2023, then surged by 1363.39% to $42.3 million in 2025, then retreated by 1.64% to $41.6 million in 2026.
• Business Quant data shows TARA's Long-Term Investments at $41.6 million in Q1 2026, $42.3 million in Q4 2025, and $957000.0 in Q3 2025.